Policy & Compliance

  • January 13, 2026

    Justices Seem Poised To Greenlight Transgender Athlete Bans

    The conservative wing of the U.S. Supreme Court voiced skepticism of allowing transgender athletes to compete in women's and girls' sports Tuesday, while also signaling a willingness to keep its ruling narrowly tailored.

  • January 13, 2026

    Blip Or Trend? FDA Guidance Fell Off Steeply In 2025

    The U.S. Food and Drug Administration issued far less industry guidance last year after President Donald Trump returned to office. The change has pharmaceutical attorneys bracing for more unpredictability.

  • January 12, 2026

    The Curious, Very Long Delay In A Pioneering Drug Prices Suit

    When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.

  • January 12, 2026

    Feds To Drop Appeal In 340B Rebate Pilot Challenge

    The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans. 

  • January 12, 2026

    ERISA Recovery Suit Against UnitedHealth Proceeds With Trims

    A UnitedHealth plan participant who was injured in a car crash may pursue claims under the Employee Retirement Income Security Act's civil enforcement provision, an Ohio federal court ruled Friday, while also allowing his wife, who was involved in a separate accident, to proceed with certain state-law claims.

  • January 12, 2026

    Yale Asks Judge To Rethink $32M Baby Formula Death Verdict

    Yale University and the affiliated Yale New Haven Hospital have asked a Connecticut state court judge to reconsider a verdict of nearly $32 million over the death of a premature baby, contending that she failed to grasp battery and informed consent law when issuing her decision after a bench trial.

  • January 12, 2026

    DC Circ. Told $100K H-1B Fee Threatens Congress' Tax Power

    The U.S. Chamber of Commerce urged the D.C. Circuit to bar the Trump administration from charging employers its new $100,000 H-1B visa fee, arguing it presents a "grave threat" to Congress' exclusive power to levy taxes.

  • January 12, 2026

    HHS' Pediatric Health Cuts Blocked As Likely 'Retaliatory'

    A D.C. federal judge has temporarily blocked the U.S. Department of Health and Human Services from cutting nearly $12 million in pediatric health funding to the American Academy of Pediatrics, finding HHS could be retaliating for a lawsuit challenging the agency's changes to members on a federal vaccine committee. 

  • January 12, 2026

    Justices Want SG Input On Arthritis Drug Competition Fight

    The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.

  • January 12, 2026

    No High Court Review For California Opioid 'Nuisance' Suit

    The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.

  • January 12, 2026

    Justices Pass On Houston Hospital Workers' COVID Vax Fight

    The U.S. Supreme Court declined Monday to hear a challenge to a Houston hospital's win in a lawsuit brought by a group of employees who said they were unlawfully terminated after refusing the COVID-19 vaccine.

  • January 09, 2026

    Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims

    A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.

  • January 09, 2026

    Up Next At High Court: Pollution Lawsuits & Trans Athletes

    The U.S. Supreme Court will kick off the new year by hearing disputes over the constitutionality of state laws banning transgender female athletes from female-only sports and whether state or federal courts are the proper forum for lawsuits seeking to hold major oil companies accountable for harm caused by their oil production activities along Louisiana's coast. 

  • January 09, 2026

    Mich. Bid For Behavioral Managed Care Contracts Can't Stand

    A Michigan Court of Claims judge ruled the state health department's bid for Medicaid managed care contract proposals would unlawfully interfere with the duties of local governmental bodies that provide and coordinate behavioral health care.

  • January 09, 2026

    Veterinary Group Says DOJ Accreditation Points Irrelevant

    The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.

  • January 09, 2026

    Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says

    Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.

  • January 08, 2026

    Walgreens Gets $392K Sanction Against Blue Cross Insurers

    A Chicago federal judge on Thursday ordered a host of Blue Cross Blue Shield insurers to pay Walgreens more than $392,000 in attorney fees and expenses for discovery misconduct in their suit that accuses the drugstore company of fraudulently overcharging for prescription drugs.

  • January 08, 2026

    9th Circ. Redo Raises New Issues On Abortion Coverage Law

    A Ninth Circuit panel that previously sided with Washington in a church's challenge to a state law mandating employer health coverage of abortion services voiced fresh concerns about both sides' positions when revisiting the case Thursday, roughly six months after rescinding the initial opinion without explanation.

  • January 08, 2026

    Ex-UnitedHealth GC Joins WilmerHale As Partner In London

    After more than 25 years as a general counsel handling some of the direst corporate crises imaginable, former UnitedHealth Group general counsel Rupert Bondy is returning to London to co-lead WilmerHale's crisis management and strategic response group.

  • January 07, 2026

    Potomac Law Adds Former DOJ, HHS Civil Rights Atty

    Potomac Law Group has hired a healthcare attorney with over 15 years working on LGBTQ+ protections and other civil rights issues at the Justice Department and the Department of Health and Human Services.

  • January 07, 2026

    Covenant Health Sued Over Patient Data Security Breach

    Nonprofit healthcare system Covenant Health Inc. has been hit with a proposed class action over a data breach that reportedly compromised the information of nearly half a million people.

  • January 06, 2026

    8th Circ. Revives Jail Suicide Suit Against Mental Health Org.

    An Eighth Circuit panel unanimously revived a lawsuit Tuesday by the family of an Iowa jail inmate who died by suicide, holding that a jury could find that a mental health provider's alleged incomplete report to jail staff put the inmate at greater risk.  

  • January 06, 2026

    Judge Hints Conn. Dentist's Press Release Claims Lack Teeth

    A Connecticut appellate judge seemed to doubt Tuesday that a dentist had asserted clear constitutional claims against state officials who issued a press release about his $300,000 False Claims Act settlement, suggesting the case might actually sound in defamation.

  • January 06, 2026

    Bankrupt Hospital Wants Out Of $3B BCBS Antitrust Deal

    A bankrupt Alabama hospital is asking a federal judge to allow it to drop out of a $2.8 billion antitrust class action settlement with Blue Cross Blue Shield, saying it may be forced to shut down unless it can pursue separate relief in bankruptcy court.

  • January 06, 2026

    The Future of The 340B Rebate Pilot

    A federal judge halted a new 340B pilot program, handing a win for safety net healthcare providers. Healthcare attorneys say it's too early for providers to celebrate.

Expert Analysis

  • Preparing For DEA Rescheduling Of 2 Research Chemicals

    Author Photo

    A recent decision to allow the U.S. Drug Enforcement Administration to reclassify two research psychedelics in Schedule I under the Controlled Substances Act may pose significant barriers to scientific study, including stringent registration requirements, heightened security protocols and burdensome reporting obligations, say Kimberly Chew at Husch Blackwell and Jackie von Salm at Psilera.

  • 9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool

    Author Photo

    The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill.

  • Fla. Misses Opportunity To Rectify Wrongful Death Damages

    Author Photo

    Florida Gov. Ron DeSantis' recent veto of a bill that would have removed certain arbitrary and unfair prohibitions on noneconomic wrongful death damages in medical negligence cases highlights the urgent need for reforms to current state law, say attorneys at Farah & Farah.

  • A Shifting Trend In FDA Form 483 Disclosure Obligations

    Author Photo

    A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.

  • The Future Of Lab-Test Regs After FDA Rescinds Rule

    Author Photo

    The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.

  • Unpacking Ore. Law's Limits On PE Healthcare Investment

    Author Photo

    A recent Oregon law imposes significant restrictions on nonphysicians owning or controlling medical practices, but newly enacted amendments provide some additional flexibility in certain ownership arrangements without scuttling the law's intent of addressing concerns about the rise of private equity investment in healthcare, say attorneys at Debevoise.

  • Criminal Healthcare Fraud Takeaways From 4th Circ. Reversal

    Author Photo

    After the Fourth Circuit reversed a doctor’s postconviction acquittal in U.S. v. Elfenbein last month, defense attorneys should consider three strategies when handling complex criminal healthcare matters, says Jonathan Porter at Husch Blackwell.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • How States Are Regulating Health Insurers' AI Usage

    Author Photo

    The absence of a federal artificial intelligence framework positions states as key regulators of health insurers’ AI use, making it important for payors and service providers to understand the range of state AI legislation being passed in California and elsewhere, and consider implementing an AI-focused compliance infrastructure, say attorneys at Ropes & Gray.

  • HHS Plan To Cut Immigrant Benefits Spurs Provider Questions

    Author Photo

    A recent notice from the U.S. Department of Health and Human Services identifying new federal public benefit programs for which nonqualified aliens are not eligible may have a major impact on entities that participate in these programs — but many questions remain unanswered, say attorneys at Foley.

  • Noncompete Forecast Shows Tough Weather For Employers

    Author Photo

    Several new state noncompete laws signal rough conditions for employers, particularly in the healthcare sector, so employers must account for employees' geographic circumstances as they cannot rely solely on choice-of-law clauses, say lawyers at McDermott.

  • Previewing State Efforts To Regulate Mental Health Chatbots

    Author Photo

    New York, Nevada and Utah have all recently enacted laws regulating the use of artificial intelligence to deliver mental health services, offering early insights into how other states may regulate this area, say attorneys at Goodwin.

  • How DOJ's New Data Security Rules Leave HIPAA In The Dust

    Author Photo

    The U.S. Department of Justice's recently effective data security requirements carry profound implications for how healthcare providers collect, store, share and use data — and approach vendor oversight — that go far beyond the Health Insurance Portability and Accountability Act, say attorneys at Nelson Mullins.